Regdanvimab

Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19[1].

Product Specifications

CAS Number

[2444308-95-4]

Product Name Alternative

CT-P59

UNSPSC

12352203

Target

Angiotensin-converting Enzyme (ACE) ; SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/regdanvimab.html

Purity

95.00

Solubility

H2O

Smiles

[Regdanvimab]

Molecular Weight

(146.22 kDa)

References & Citations

[1]Ryu DK, et al. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021 Nov 12;578:91-96.